Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Present at Upcoming Sidoti Conference

Friday, November 10, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. will present at the Sidoti Conference, showcasing its advanced gene editing capabilities. The company employs its proprietary ARCUS platform to develop in vivo gene editing therapies. This presentation highlights the company's commitment to sophisticated gene edits, including insertion, excision, and elimination.
Price reaction · baseline $11.82 (2023-11-09 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-3.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is presenting at a notable conference.
  • The company is advancing gene editing therapies.
  • Utilization of the proprietary ARCUS platform shows innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Nov. 10, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

Frequently Asked Questions

What is the focus of Precision BioSciences?

Precision BioSciences focuses on advanced gene editing therapies.

What platform does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for gene editing.

When is the Sidoti Conference?

The Sidoti Conference is scheduled for November 10, 2023.

What types of gene edits are developed?

The company develops therapies for gene insertion, excision, and elimination.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences Sidoti Conference gene editing ARCUS platform
Last updated: Nov 10, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →